


PATRONAGES - UNDER THE AUSPICES OF



WITH THE UNCONDITIONAL SUPPORT OF

PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



GENERAL INFORMATION

REGISTRATION

Registration is free of charge.

You may register for IN-PERSON ACCESS

<https://www.events-communication.com/event/lungcancer2026/>

<https://www.lungcancer-milan.com/>

For information: segreteria@events-communication.com

CONGRESS VENUE

Aula Magna - Fondazione IRCCS Istituto Nazionale Tumori

Via Giacomo Venezian, 1 20133 Milan (Italy)

OFFICIAL LANGUAGE AND TIME

The official language is English. The official Time is Central European Time (CET), UTC +1

C.M.E. CREDITS

CME accreditation (valid for Italian participants only) for: Medical Doctor.

RES ID CME 488144 CME RES credits: 4,9

Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER



Events srl

Via L. Lotto 9, 60019 Senigallia (AN)

Via Sabotino 14, 20135 Milano (MI)

www.events-communication.com



7th Edition LUNG CANCER COCKTAIL WITH SCIENCE 2026

DECEMBER 21st - MILAN, ITALY

SCIENTIFIC PROGRAM

10.00	Registration
10.30	Introduction and objectives Giuseppe Lo Russo
10.40	Welcome addresses (Italian language) Gustavo Galmozzi , <i>President Fondazione IRCCS INT</i> Maria Teresa Montella , <i>General Director Fondazione IRCCS INT</i> Ruggero De Maria* , <i>Scientific Director Fondazione IRCCS INT</i> Filippo de Braud , <i>Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS INT</i> Massimo Di Maio , <i>President AIOM</i>
1	SESSION NSCLC EARLY AND LOCALLY ADVANCED DISEASE <i>Chairs:</i> G. Corrao, A. De Toma, G. Viscardi
11.00	SPECIAL LECTURE Biomarkers for early diagnosis of lung cancer Gabriella Sozzi
11.20	Upfront Surgery: When? Lobectomy,segmentectomy,atypical resection for whom and why? Piergiorgio Solli
11.35	Adjuvant, Neoadjuvant and Peri-operative approach, new perspectives in wt NSCLC Tina Cascone
11.50	Not-resectable wt locally advanced disease Andrea Riccardo Filippi
12.05	The role for Target therapies in early and locally advanced disease Giannis Mountzios

12.20	Round Table and Questions All
13.00	LUNCH
2	SESSION NSCLC ONCOGENE ADDICTED ADVANCED DISEASE <i>Chairs:</i> G. Galli, C. Proto, R. Romanò
14.00	SPECIAL LECTURE The importance of tumor mutational board in oncology. Is the lung cancer model applicable to other neoplasms? Giancarlo Pruneri
14.20	Liquid biopsy: are we ready for use in clinical practice? Christian Rolfo
14.35	New perspectives for EGFR mutated patients Luis Paz Ares
14.50	Updates for BRAF, MET, HER2 positive patients Federico Cappuzzo
15.05	Current treatment algorithms for ALK, ROS1, RET, NTRK positive patients Shirish Gadgeel
15.20	Round Table and Questions All
15.50	COFFEE BREAK


3	SESSION NSCLC ADVANCED DISEASE: WT AND KRAS MUTATED <i>Chairs:</i> M. Brambilla, R. Ferrara, L. Mazzeo
16:10	SPECIAL LECTURE Reprogramming metabolism as a treatment strategy in solid tumors Claudio Vernieri
16.30	How to improve first-line therapy for patients with wt NSCLC? Marina Chiara Garassino
16.45	New Strategies for wt NSCLC progressive to first line treatment Heather Wakelee
17.00	K-RAS mutated patients: a revolution is coming Helena Linardou
17.15	Round Table and Questions All
4	SESSION A LOOK BEYOND NSCLC <i>Chairs:</i> P. Ambrosini, M.Occhipinti, D. Signorelli
17.40	SCLC light at the end of the tunnel? Stephen V. Liu
17.55	Thymic Neoplasms updates Jordi Remon Masip
18.10	Pleural Mesothelioma: state of the art Luana Calabrò
18.25	Round Table and Questions All
18.50	Conclusions remarks Giuseppe Lo Russo
19.00	COCKTAIL

OVERVIEW

The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment.

PRESIDENT OF THE CONFERENCE

GIUSEPPE LO RUSSO
Thoracic Unit , Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT



FACULTY

Paolo Ambrosini, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Marta Brambilla, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Luana Calabrò, Associate Professor of Medical Oncology at the University of Ferrara and Director of the Clinical Oncology Unit at the Ferrara University Hospital

Federico Cappuzzo, Department of Medical Oncology 2, IRCCS Istituto Nazionale Tumori Regina Elena, Rome IT

Tina Cascone, Associate Professor, Dpt. of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX USA

Giulia Corrao, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Alessandro De Toma, Oncology Department, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan IT

Roberto Ferrara, Thoracic Oncology, Molecular Immunology, IRCCS Ospedale San Raffaele, Milano IT

Andrea Riccardo Filippi, Associate Professor in Radiation Oncology at the University of Milan and Head of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Shirish Gadgeel, Division Head for Hematology/Oncology, Associate Director, Patient Experience and Clinical Care, Henry Ford Cancer Institute, Detroit MI USA

Giulia Galli, Oncology Unit, Department of Oncology - Comprehensive Cancer Center, Fondazione IRCCS Policlinico San Matteo, Pavia IT

Marina Chiara Garassino, Professor of Medicine and Director of Thoracic Programs in the Section of Hematology/Oncology, University of Chicago, ILL USA

Helena Linardou, Director of the 4th Oncology Dpt. and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens GR

Stephen V. Liu, Medical Oncologist, Associate Professor of Medicine, Director of Thoracic Oncology, Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University, Washington, DC USA

Giuseppe Lo Russo, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Laura Mazzeo, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giannis Mountzios, Director of the 4th Oncology Dpt. and Clinical Trials Unit, Henry Dunant Hospital Center, Athens GR

Mario Occhipinti, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Luis Paz Ares, Chair of the Medical Oncology Dpt. at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense de Madrid and Head of the Lung Cancer Unit at the CNIO (Spanish National Oncology Research Center), Madrid ES

Claudia Proto, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giancarlo Pruneri, Director of the Postgraduate School of Pathology at University of Milan and Director of the Dpt. of Services and Advanced Diagnostics/Head of Pathological Anatomy 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Jordi Remon Masip, Dpt. of Cancer Medicine, Gustave Roussy Institut, Villejuif FR

Christian Rolfo, Professor of Medicine at the Ohio State University, School of Medicine/Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials, James Comprehensive Cancer Center at OSU, Columbus OH USA

Rebecca Romanò, Thoracic Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Diego Signorelli, Medical Oncology, ASST Grande Ospedale Metropolitano Niguarda, Milano IT

Piergiorgio Solli, Head of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Gabriella Sozzi, Head of Epigenomics and Biomarkers of Solid Tumors Unit and Head of Dpt. of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Claudio Vernieri, Breast Unit, Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Giuseppe Viscardi, Oncology Unit, Monaldi Hospital, AORN Ospedali dei Colli, Naples IT

Heather Wakelee, Professor of Oncology, Stanford University Medical Center, Stanford USA

*Invited